The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
Plasma Protein Forum Highlights +
The 2015 Plasma Protein Forum concluded June 17 with panels that covered industry challenges, patient voices, benefits of plasma donation, self-sufficiency, and regulatory issues. More than 300 people from across the industry attended the two-day event in Washington, D.C.Read More
New PPF App Available for Download +
PPTA Mourns Passing of Dr. Víctor Grífols Lucas +
Sadly we learned that Dr. Víctor Grífols Lucas passed away on June 1, 2015, in Barcelona, Spain. PPTA sends its condolences to the Grifols family as well as the thousands of employees of the Grifols company with the loss of one of the founders of Laboratorios Grifols.Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly. Read the current issue.